Le Lézard
Classified in: Health
Subject: SVY

Global obesity surgery devices market size is forecasted to attain a value of $2.8 billion by 2023


LONDON, Jan. 23, 2018 /PRNewswire/ -- Global obesity surgery devices market size is forecasted to attain a value of $2.8 billion by 2023 growing at a CAGR of 9.9% during 2017-2023.



Download the full report: https://www.reportbuyer.com/product/5289035



The boost in demand for the obesity surgery devices is due to various factors such as increasing prevalence of obesity leading to high demand for obesity surgeries, rising awareness about bariatric surgery in obese population, lifestyle changes leading to high risk of obesity, and technological advancements in the obesity surgery devices industry.


Insights on market segments
Minimally invasive and non-invasive surgeries are performed for treating obesity. The different minimally invasive surgeries performed are sleeve gastrectomy, gastric bypass, gastric banding, biliopancreatic diversion surgeries with a duodenal switch (BPD-DS) and several others. Sleeve gastrectomy surgery devices held the largest share in the obesity surgery devices market, since these surgeries result in more weight loss and have a low mortality rate, when compared to other alternative surgical procedures.

The market for sleeve gastrectomy is expected to witness the fastest growth during the forecast period at a CAGR of 13.2%.
Obesity surgery is performed using several devices that are available in the market including stapling devices, gastric bands, gastric balloons, gastric electric stimulators and several others. Stapling devices held the largest share of the global obesity surgery devices market in 2016, owing to their high application in almost all types of bariatric surgeries to staple the stomach and intestine parts.

Asia?Pacific stands as the fastest growing market for obesity surgery devices
Asia?Pacific is expected to observe the fastest growth in the obesity surgery devices market, due to increasing aging population, rising prevalence of obesity, and booming medical tourism in the region.

According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the number of people aged 65 years and above constituted approximately 11.4% of population in 2013, and the count is estimated to reach approximately 20% of the population, by 2050. As a result, an increase in the demand for devices for obesity surgery is expected to increase in the region.

Also, according to the Organization for Economic Co-operation and Development (OECD), there is a steady increase in the obesity rate until 2030. Obesity rates are projected to increase at a faster pace in Korea where rates have been historically low. This is thus increasing the demand for products in the obesity surgery devices market.

Key competitors in the market are launching new and innovative products to gain a larger share
Globally, the key players in the obesity surgery devices market are launching new products to gain a larger market share. For instance, in April 2017, Intuitive Surgical, Inc., announced that the company had received CE Mark approval in Europe for its da Vinci X Surgical system. This approval expanded the company's product portfolio and also provided surgeons and hospitals with advanced robotic assisted surgical technology at an affordable range.

In May 2016, Apollo Endosurgery, Inc., along with Zillion technologies Inc., announced the launch of ORBERA Coach platform that would provide telehealth monitoring of patients undergoing ORBERA Gastric Balloon procedure.

ORBERA Coach is a telehealth aftercare program that allows patients to access exercise, nutrition, and other coaching resources via on demand interaction with registered dietitians trained on the ORBERA procedure during the 12 months following placement of the ORBERA gastric balloon. These developments are likely to add to the growth of the obesity surgery devices market.

Other key manufacturers operating in the obesity surgery devices industry include Medtronic plc, Johnson & Johnson, Spatz FGIA Inc., W. L. Gore & Associates, Inc., ReShape Lifesciences, Inc. (formerly EnteroMedics Inc.), and Cousin Biotech.

Download the full report: https://www.reportbuyer.com/product/5289035

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

 

SOURCE ReportBuyer


These press releases may also interest you

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...



News published on and distributed by: